

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

DR. JOHN MOLLOY (Orcid ID : 0000-0002-6935-0418)

Received Date : 21-Jun-2016

Revised Date : 27-Dec-2016

Accepted Date : 31-Dec-2016

Article type : Original Article: Epidemiology and Genetics

Editor : Bodo Niggemann

Allergy

Vitamin D insufficiency in the first 6 months of infancy and challenge-proven IgE-mediated food allergy at 1 year of age: a case-cohort study.

John Molloy, MB Bao Bch, MRCPI,^{1,2,3,4}; Jennifer J. Koplin, PhD,^{3,4,5}; Katrina J. Allen, MBBS, BMedSc, FRACP, PhD,^{3,4,6,7}; Mimi L.K. Tang, MBBS, FRACP, FRCPA, PhD,^{3,4,6,7}; Fiona Collier, PhD,^{1,2,3}; John B. Carlin, PhD,^{3,5,6}; Richard Saffery, PhD,³; David Burgner, MB ChB, FRACP, PhD,^{3,6,8}; Sarath Ranganathan, MB ChB, MRCP, FRCPCH, FRACP, PhD,^{3,6,9}; Terence Dwyer, PhD,¹⁰; Alister C. Ward, PhD,¹; Margarita Moreno-Betancur, PhD,^{3,11}; Michael Clarke, PhD,¹²; *Anne Louise Ponsonby, MBBS, PhD,^{3,4}; *Peter Vuillermin, MBBS, FRACP, PhD,^{1,2,3,4}; on behalf of the BIS investigator group

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/all.13122](https://doi.org/10.1111/all.13122)

This article is protected by copyright. All rights reserved

24 **AFFILIATIONS:**

25 ¹*Deakin University, School of Medicine, Waurn Ponds, Australia*

26 ²*Child Health Research Unit, Barwon Health, Geelong, Australia,*

27 ³*Murdoch Childrens Research Institute, Parkville, Australia,*

28 ⁴*Centre for Food and Allergy Research, Parkville, Australia,*

29 ⁵*The University of Melbourne, Centre for Epidemiology and Biostatistics, Carlton, Australia.*

30 ⁶*Department of Paediatrics, University of Melbourne, Parkville, Australia*

31 ⁷*Department of Allergy and Immunology, Royal Children's Hospital, Parkville, Australia,*

32 ⁸*Department of Paediatrics, Monash University, Clayton, Australia.*

33 ⁹*Department of Respiratory Medicine, Royal Children's Hospital, Parkville, Australia,*

34

35 ¹⁰*The George Institute for Global Health, University of Oxford, United Kingdom*

36 ¹¹*Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,*
37 *Australia*

38 ¹²*Metabolomics Australia, Centre for Microscopy, Characterisation and Analysis, University of*
39 *Western Australia, Western Australia.*

40 *Denotes equal contribution

41 **CORRESPONDING AUTHOR:**

42 **Assoc/Prof. Peter Vuillermin,**

43 **Child Health Research Unit,**

44 **Kitchener House,**

45 **Ryrie Street,**

46 **Geelong,**

47 **Victoria, 3220,**

48 **Australia.**

49 **Email: peter.vuillermin@deakin.edu.au**

50 **Telephone: +61342153384**

51

52 **Funding**

53 The establishment work and infrastructure for the BIS was provided by the Murdoch
54 Childrens Research Institute, Deakin University and Barwon Health. Subsequent funding was
55 secured from the National Health and Medical Research Council of Australia, The Jack
56 Brockhoff Foundation, the Scobie Trust, the Shane O'Brien Memorial Asthma Foundation,
57 the Our Women's Our Children's Fund Raising Committee Barwon Health, The Shepherd
58 Foundation, the Rotary Club of Geelong, the Ilhan Food Allergy Foundation and GMHBA.
59 Support in kind has been provided by The Cotton On Foundation and CreativeForce.

60

61

62

63

64

65

66 **Abstract**

67 **Background**

68 Ecological evidence suggests vitamin D insufficiency (VDI) due to lower ambient ultraviolet
69 radiation (UVR) exposure may be a risk factor for IgE-mediated food allergy. However there
70 are no studies relating directly measured VDI during early infancy to subsequent challenge-
71 proven food allergy.

72 **Objective**

73 To prospectively investigate the association between VDI during infancy and challenge-
74 proven food allergy at 1 year.

75 **Methods**

76 In a birth cohort (n=1074), we used a case-cohort design to compare 25-hydroxy-vitamin-D₃
77 (25(OH)D₃) levels among infants with food allergy versus a random subcohort (n=274). The
78 primary exposures were VDI (25(OH)D₃<50 nmol/L) at birth and 6 months of age. Ambient
79 UVR and time in the sun were combined to estimate UVR exposure dose. IgE-mediated food
80 allergy status at 1 year was determined by formal challenge. Binomial regression was used to
81 examine associations between VDI, UVR exposure dose and food allergy, and investigate
82 potential confounding.

83

84 **Results**

85 Within the random subcohort VDI was present in 45% (105/233) of newborns and 24%
86 (55/227) of infants at 6 months. Food allergy prevalence at 1 year was 7.7% (61/786) and
87 6.5% (53/808) were egg allergic. There was no evidence of an association between VDI at
88 either birth (aRR 1.25, 95% CI 0.70-2.22) or 6 months (aRR 0.93, 95% CI 0.41-2.14) and
89 food allergy at 1 year.

90 **Conclusions**

91 There was no evidence that VDI during the first 6 months of infancy is a risk factor for food
92 allergy at 1 year of age. These findings primarily relate to egg allergy and larger studies are
93 required.

94

95

96

97

98 **Key words:** cohort; eczema; food allergy; paediatrics; vitamin D;

99

100 **Abbreviations:**

101 UVR: Ultraviolet Radiation

102 VDI: vitamin D insufficiency

103 25(OH)D₃: 25-hydroxy-vitamin-D₃

104 25(OH)D: 25-hydroxy-vitamin-D

105 BIS: Barwon Infant Study

106 C3-epi-25(OH)D₃: C3-epimeric-25-hydroxyvitamin D₃

107 2D LC-MS/MS: two-dimensional ultra-performance liquid chromatography separation
108 coupled tandem mass spectrometry

109 SCORAD: Scoring Atopic Dermatitis Scale

110 RR: Risk Ratio

111 aRR: adjusted Risk Ratio

112

Author Manuscript

114 **Introduction**

115 A concordant increase in allergic disease prevalence (1-6) and decrease in vitamin D status
116 (7) has been reported in both developed and developing countries. This correlation has led to
117 the hypothesis that low vitamin D status may influence the development of allergic disease
118 including food allergy and eczema (8). Consistent with this, observational studies have found
119 associations between proxy markers of ultraviolet radiation (UVR) exposure, the major
120 source of vitamin D (9), and allergic disease. Latitudes further from the equator appear to be
121 associated with higher rates of food allergy and eczema (10-12); and less consistently,
122 autumn and winter births (periods of low UVR exposure (13)) may be more common among
123 infants and children with food allergy (14-16). There is a substantial literature describing the
124 biological mechanisms by which vitamin D may influence the risk of developing allergic
125 disease (8) including effects on regulatory T cells (17) and bowel epithelial integrity (18).
126 Moreover, ambient UVR has also been shown to affect immune modulation via non-vitamin
127 D pathways (19) and may independently protect against allergic disease development (20).

128 A previous study reported a cross-sectional association between vitamin D₃ insufficiency
129 (VDI; 25(OH)D₃ <50 nmol/L) and challenge-proven IgE-mediated food allergy among one-
130 year-old infants of Australian-born parents, with evidence of a dose-response relationship
131 (21). However the findings from prospective studies regarding directly measured maternal
132 and infant vitamin D (25(OH)D) (22-26) or 25(OH)D₃ (27, 28) and subsequent allergic
133 outcomes are conflicting, and limited by incomplete measurement of potential confounding
134 factors and suboptimal case definition (22-28). Further, there has been minimal investigation
135 of the potential role of UVR exposure in reducing risk of allergic disease independent of
136 25(OH)D pathways (29); and the hypothesis that the association between VDI and food
137 allergy may be modified by microbial exposure has not been adequately tested (8).

138 The primary objective of this study was to utilise a population-derived birth cohort with
139 detailed measurement of relevant covariates to prospectively evaluate the relationship
140 between VDI during the first 6 months of infancy and challenge-proven IgE-mediated food
141 allergy at 1 year of age. In addition, we evaluated the relationship between UVR exposure
142 and food allergy; as well as the relationship between VDI, UVR exposure and eczema.

143

144 **Methods**

145 **Study design**

146 The aims and methodology for the Barwon Infant Study (BIS) have been described
147 previously (30). Briefly, a birth cohort of 1074 mother-infant pairs was assembled in the
148 southeast of Australia using an unselected antenatal sampling frame. The Barwon region
149 population characteristics are similar to those of the Australian population overall, but with a
150 smaller proportion of families from non-English-speaking backgrounds (30). Mother-infant
151 pairs were reviewed at regular intervals during pregnancy and the first year of life. Eczema
152 symptoms and signs were recorded at each review and challenge-proven food allergy status
153 was determined at 1 year. Among the infants who completed the 1 year review, 31%
154 (274/894) were randomly selected to comprise the 'random subcohort'. 25(OH)D₃ was
155 measured among infants in this subcohort as well as in those who had a positive food skin
156 prick test (SPT) and/or had clinically proven food allergy. To minimise selection bias,
157 analysis of the distribution and determinants of 25(OH)D₃, and analysis of the association
158 between 25(OH)D₃ and eczema, was restricted to infants within the random subcohort.
159 Relationships between UVR exposure dose and food allergy or eczema were investigated in
160 the full BIS cohort.

161 **Exposure measures**

162 *Vitamin D status*

163 Blood samples were collected at four time points: maternal at 28-32 weeks gestation, infant at
164 birth (cord blood), 6 months and 1 year (mean 13.03 months \pm S.D. 0.83). The 25(OH)D₃
165 metabolites (serum or plasma) and epimeric form, C3-epi-25-hydroxyvitamin D₃ (C3-epi-
166 25(OH)D₃) were measured using two-dimensional ultra-performance liquid chromatography
167 separation coupled tandem mass spectrometry detection (2D LC-MS/MS) (31). VDI was
168 defined as 25(OH)D₃ <50 nmol/L and vitamin D deficiency as 25(OH)D₃ <25 nmol/L, levels
169 which are based predominantly on markers of bone health (32, 33). An appropriate definition
170 of VDI in relation to immune health remains uncertain.

171 *UVR exposure*

172 Questionnaire data quantifying exposure to direct sunlight daily were recorded during
173 trimesters 1 and 2 of pregnancy, and at 4 weeks, 6 months and 1 year. The ambient UVR was
174 estimated using monthly averages of daily total ambient UVR in standard erythemal doses

175 (34) for Melbourne from 2010 to 2014, provided by the Australian Radiation Protection and
176 Nuclear Safety Agency. Total UVR exposure dose was calculated as the product of time in
177 direct sun and the average of the daily ambient UVR exposure. A total cumulative postnatal
178 UVR exposure dose over the first year of life was estimated by dividing UVR exposure at 4
179 weeks, six months and twelve months into tertiles and assigning each tertile a score
180 (0=lowest, 1= moderate and 2=highest). These scores were then summed to generate a
181 cumulative postnatal UVR exposure dose score (lowest=0, highest=6) (35). A categorical
182 score was created describing the parental report of sunscreen use during infant sun exposure.
183 The score was included in a secondary analysis to test for the modifying effect sunscreen may
184 have on actual personal UVR exposure (35).

185 **Outcome measures**

186 *Food allergy status*

187 At the 1 year review, infants underwent a SPT to five foods: cow's milk, egg, peanut, cashew
188 and sesame (ALK-Abelló, Madrid, Spain) with a positive (10 mg/ml histamine) and negative
189 (saline) control. Quintip® lancets (Hollister-Stier Laboratories, Spokane, WA) were used to
190 perform SPT's on infant's backs. In clinical practice food sensitisation at 1 year of age is
191 defined as a SPT wheal size 3mm or greater than the negative control in the presence of a
192 positive histamine control (36), however recent studies have used a definition of 2mm or
193 greater than the negative control in infants (21). A food allergen SPT wheal size of at least 2
194 mm greater than the negative control in the presence of a positive histamine control was
195 defined as food sensitised in this study. All participants with SPT wheals 1 mm or more
196 greater than the negative control were offered an in-hospital open food challenge (4). Those
197 regularly ingesting the sensitised food at the time of SPT were defined as sensitised tolerant
198 without formal challenge (n=12). If, on clinical review, the participant had a clinical history
199 and reaction consistent with a diagnosis of IgE-mediated food allergy within 2 months of the
200 1 year review and a positive SPT, they were defined as food allergic without proceeding to
201 food challenge (n=3) (4). Open food challenges (including raw egg) were performed under
202 clinical supervision using validated protocols from the HealthNuts study (4). A positive
203 challenge comprised one or more of the following criteria occurring within 2 hours of
204 ingesting a dose of challenge food (4) :

- 205 • three or more concurrent non-contact urticaria for five minutes or longer;

- 206 • vomiting or diarrhoea;
- 207 • angioedema;
- 208 • anaphylaxis (circulatory or respiratory compromise).

209 These criteria were also used to define an IgE-mediated reaction occurring during the
210 subsequent week-long home-based introduction if they had not reacted during the clinic
211 challenge (n=1) (4). A negative challenge was defined by the full ingestion of the highest
212 dose of the challenge food with no reaction and completion of the subsequent home-based
213 introduction without reaction. The refusal of the child to eat the challenge food or complete
214 all doses in the challenge protocol was deemed an inconclusive challenge (n=5).

215 *Eczema status*

216 Data on eczema were collected by questionnaires administered at 1, 3, 6, 9 months and 1
217 year; and clinical assessments were conducted at 1 month, 6 months and 1 year. Eczema was
218 defined according to the modified UK working party criteria (37, 38). All infants had to have
219 a history of itchy skin plus at least three of the following: a history of dry skin, a family
220 history of allergy, a history of skin rash affecting the flexures or outer surfaces of the limbs or
221 affecting the head or cheeks, or visible dermatitis assessed during a study visit at either 1
222 month, 6 months or 1 year (39). The Scoring Atopic Dermatitis Scale (SCORAD) was used
223 to quantify eczema severity (40, 41).

224

225

226 **Statistical analysis**

227 Our primary hypothesis was that VDI in the first 6 months of infancy would be associated
228 with food allergy at 1 year of age. Infants with an inconclusive hospital food challenge result
229 or indeterminate food allergy status were excluded from the food allergy analysis (n=30).
230 For the food allergy case-cohort analysis we applied inverse probability weighting where the
231 probability of selection for non-cases in the random subcohort was estimated by the fraction
232 of infants included in the subcohort from the total cohort reviewed at 12 months in the BIS
233 study (274/894). The probability of selection for food allergy cases was 1 (42).

234 Categorical variables were summarised using proportions. A propensity weighting approach
235 was used to adjust the eczema prevalence to account for loss to follow-up over the first year
236 of the study and provide an estimated eczema prevalence over the first year for the inception
237 cohort (43). T-tests were used to compare the mean 25(OH)D₃ levels between food allergic
238 infants and the random subcohort, and between infants within the random subcohort with and
239 without eczema (Supplemental Tables EI and EII). Binomial regression models were fitted to
240 estimate risk ratios (RR) for associations between exposures (VDI and UVR exposure dose)
241 and food allergy at 1 year of age or eczema. A further analysis examined the associations
242 between VDI and food sensitisation. 25(OH)D₃ was also divided into quintiles to assess
243 potential non-linear associations and thresholds other than 50 nmol/L (Supplemental Figures
244 E3 & E4).

245 Ethnicity, family history of allergy, number of siblings, formula feeding and pet ownership
246 were selected *a priori* to be included as covariates in the model as they have each been
247 related to both 25(OH)D₃ and allergic disease. Smoking, livestock ownership, socioeconomic
248 status (SES), birth weight, gender, season of birth, egg avoidance and time of solid
249 introduction in infancy, maternal and infant vitamin D supplementation, C3-epi-25(OH)D₃
250 (31) concentration and mode of delivery at birth were retained in the model if they made a
251 greater than 10% change to the risk ratio point estimate.

252 The relationship between change in 25(OH)D₃ status over the first 6 months of life and food
253 allergy at 1 year of age was investigated by fitting a multivariable binomial regression model,
254 using 25(OH)D₃ at birth as a baseline variable, and change in 25(OH)D₃ status from birth to
255 6 months of age as an explanatory variable (44). An interaction term was specified to
256 investigate effect modification by pet ownership (8).

257 To adjust for seasonal variation in 25(OH)D₃ levels, we fitted a sinusoidal curve with a
258 period of 12 months to 25(OH)D₃ data using linear regression, and added the residuals from
259 this model to the population average 25(OH)D₃ levels (45). For the C3-epi-25(OH)D₃
260 sensitivity analysis, C3-epi-25(OH)D₃ and 25(OH)D₃ were summed as a new variable
261 representing total vitamin D exposure for the binary regression.

262 Analyses were performed using Stata (version 14.1, College Station, Texas).

263 **Ethics**

264 The study was approved by Barwon Health Human Research and Ethics Committee (HREC
265 10/24). Parents or guardians provided written informed consent for this study.

266

267

268 **Results**

269 **Study population**

270 The majority of participants were full term, Caucasian infants with Australian born parents
271 (Table 1). The majority of mothers took vitamin D supplements during pregnancy and up to
272 one third of infants were exposed to formula feeding (Table 1).

273

274 **Vitamin D levels within the random subcohort**

275 Within the random subcohort vitamin D₃ levels were measured among 233 infants at birth
276 and 227 infants at six months. (Supplemental Figure E1). Forty five percent (105/233) of
277 infants had VDI at birth and 24% (55/227) at 6 months. More than 82% of mothers reported
278 taking a supplement containing vitamin D during pregnancy and maternal VDI was
279 uncommon (9%), (Table I and Figure 1). The average ratio of birth 25(OH)D₃ to maternal
280 25(OH)D₃ was 0.61. The mean change in 25(OH)D₃ status from birth to 6 months was +15.0
281 nmol/L ± S.D. 34.0 nmol/L.

282 **Determinants of vitamin D status**

283 At each time point, ambient UVR 6 weeks prior to blood draw was associated with
284 25(OH)D₃ status (Supplemental Table EVI). VDI in the first 6 months of life was less
285 common among infants who were formula fed and who had no siblings (Supplemental Table
286 EVI).

287 **Food allergy and eczema prevalence**

288 Of the 1074 eligible infants in the inception cohort, 83.2% (894) completed the 1 year review.
289 91.6% (819/894) of these had a valid skin prick test; and 82% (92/114) infants with a skin
290 prick reaction to a food at least 1 mm larger than the negative control subsequently attended a

291 formal in-hospital food challenge. A total of 58 had positive food challenges and 3 had
292 previous clinical reactions meeting the criteria for clinically proven IgE-mediated food
293 allergy. The prevalence of challenge-proven food allergy among infants completing the 1
294 year review with valid outcome measures was 7.7% (95% CI, 6.0-9.8), with egg allergy the
295 most common, 6.5% (95% CI, 5.0-8.4) (Table II).

296 Eczema point prevalence rates in the cohort were: 0% at 1 month; 1.2% (12/973) at 3 months;
297 8.5% (78/923) at 6 months; 13.6% (120/880) at 9 months; and 8% (71/884) at 1 year. The
298 estimated eczema prevalence over the first year of life for the inception cohort was 24.2%
299 (95% CI 21.2%-27.3%). The average SCORAD in infants with eczema at 6 months was 9.9
300 (S.D. 11.4) with 69% (54/78) having a score consistent with mild disease (41) At 1 year the
301 average SCORAD was 6.6 (S.D. 8.4) with 86% (61/71) having a score consistent with mild
302 disease.

303

304

305

306 **Vitamin D status and IgE-mediated food allergy**

307 There was no evidence of an association between VDI at either birth (aRR 1.25, 95% CI
308 0.70-2.22) or 6 months (aRR 0.93, 95% CI 0.41-2.14) and food allergy at 1 year of age
309 (Figure 2). Analyses using deseasonalised 25(OH)D₃ (Supplemental Figure E2 & Table EI)
310 showed similar patterns of associations to the primary analysis. The mean 25(OH)D₃ level
311 was similar at birth (Mean Difference 2.10 nmol/L, 95% CI -3.70-7.91) and 6 months (Mean
312 Difference -2.16 nmol/L, 95% CI -10.2-5.9) among infants with and without food allergy at 1
313 year of age (Supplemental Table EI). There was no evidence of an association between
314 25(OH)D₃ < 25 nmol/L at birth and food allergy at 1 year of age (p=0.94). At each timepoint,
315 there was some non-linearity between 25(OH)D₃ levels and food allergy risk (Supplemental
316 Figures E3 & E4) but there was no evidence to support the use of a threshold other than 50
317 nmol/L.

318 There was no evidence that change in 25(OH)D₃ status from birth to 6 months of age was
319 associated with food allergy at 1 year of age (aRR 0.99, 95% CI 0.96-1.02). Adjusting for C3-

320 epi-25(OH)D₃ in maternal samples, at birth or 6 months by adding to the 25(OH)D₃ level did
321 not change the lack of association between 25(OH)D₃ and food allergy (Supplemental Table
322 EIII).

323 There was no evidence that the lack of association between VDI during the first 6 months of
324 infancy and food allergy at 1 year of age was modified by pet ownership status as a marker of
325 microbial experience (p=0.96).

326 There was also no association evident between maternal VDI and offspring food allergy at 1
327 year of age (aRR 0.45 95% CI 0.06-3.47) (Supplemental Table EI), and only a weak
328 indication of a cross-sectional association between VDI and food allergy at 1 year of age
329 (aRR, 1.89 95% CI 0.86-4.13) (Figure 2).

330 **Vitamin D status and eczema**

331 Within the random subcohort there was no evidence of an association between VDI at either
332 birth (aRR 0.88, 95% CI 0.54-1.43) or 6 months (aRR 0.84, 95% CI 0.33-2.14) and subsequent
333 eczema (Figure 3). Adjustment for potential confounders made <10% difference to the
334 estimated risk ratios. Analysis using deseasonalised 25(OH)D₃ also indicated no association
335 between VDI and eczema (Supplemental Table EII & Figure E5).

336

337 **Ambient UVR exposure dose and IgE-mediated food allergy**

338 In the full cohort analysis there was no evidence of a prospective association between UVR
339 exposure dose at individual time points, and food allergy at 1 year of age (Figure 4 &
340 Supplemental Table EIV). Similarly, there was no evidence of a prospective association
341 between maternal or infant UVR exposure dose and eczema in the first year of life
342 (Supplemental Figure E6 & Table EV). There was no evidence that the relationship between
343 UVR exposure and food allergy was modified by any level of sunscreen use (p=0.32 for
344 moderate UVR exposure, p=0.92 for high UVR exposure).

345

346

347 **Vitamin D status and food sensitisation**

348 *Food sensitisation at year 1 defined as a SPT wheal size 3mm or greater than the negative*
349 *control:* There was no evidence that VDI at any time point was associated with food
350 sensitisation (Supplemental Table EVII). *Food sensitisation at year 1 defined as a SPT wheal*
351 *size 2mm or greater than the negative control:* There was no evidence of an association
352 between VDI during pregnancy or at birth and food sensitisation. There was however weak
353 evidence of associations between VDI at six (p=0.04) and twelve months (p=0.04) and food
354 sensitisation defined using this more inclusive threshold (≥ 2 mm) (Supplemental Table
355 EVIII).

356

357

358 **Discussion**

359 This is the first study to investigate 25(OH)D₃ measured during the first 6 months of infancy
360 in relation to challenge-proven food allergy at 1 year of age. In a predominantly Caucasian
361 cohort, among whom raw egg was the most common food allergy, there was no evidence of
362 an association between infant VDI during the first 6 months of infancy and IgE-mediated
363 food allergy at 1 year of age or eczema. There was also no evidence of an association
364 between estimated UVR exposure dose and either food allergy or eczema.

365 VDI was present in almost half of the infants at birth and a quarter of infants at 6 months of
366 age. Egg avoidance, the absence of formula feeding and a greater number of siblings were
367 each associated with increased risk of VDI during infancy. However, a large proportion of the
368 variation in vitamin D status remained unexplained and unmeasured genetic factors are likely
369 to be important (35). Food allergy prevalence, whilst less common than observed in the
370 Australian HealthNuts study (4), was still substantially higher than recent reports from
371 Europe with similar outcomes (46, 47).

372

373 Over the last decade there has been intense interest in the potential relationship between VDI
374 and food allergy, given a range of ecological findings and a wealth of mechanistic studies
375 regarding the influence of 25(OH)D₃ on gut epithelial integrity (18, 48, 49) and immune
376 function (17). However the data from studies relating directly measured 25(OH)D or
377 25(OH)D₃ during early infancy to various markers of allergic disease are conflicting. Early
378 papers reported positive associations between low cord blood 25(OH)D and subsequent

379 allergic sensitisation (50, 51) and eczema (52). Another study using cord blood 25(OH)D₃
380 also reported similar associations with eczema (27). More recent studies have been unable to
381 replicate these positive associations using either 25(OH)D (22, 53) or 25(OH)D₃ (28) as the
382 exposure. The current paper extends the body of evidence against a prospective association
383 between VDI and allergy by measuring 25(OH)D₃ at two time-points during early infancy
384 and including the more robust and clinically relevant measure of challenge-proven food
385 allergy status.

386

387 Birth 25(OH)D₃ was generally around sixty percent of the maternal level, consistent with
388 previous studies (54). Thus relatively lower 25(OH)D₃ levels in cord blood may be
389 physiological, and it is uncertain whether a cut-off of 50 nmol/L to define VDI in cord blood
390 is appropriate, particularly as this threshold is based predominantly on markers of bone health
391 in adults (32) and an appropriate immune related level remains uncertain. Accordingly, we
392 explored a range of threshold levels including 25(OH)D₃ < 25 nmol/L as well as 25(OH)D₃
393 quintiles, but remained unable to identify a relationship between cord 25(OH)D₃ and food
394 allergy at 1 year of age.

395

396 It has been proposed that 25(OH)D₃ status may be particularly important during the period of
397 introduction of dietary solids (8, 55). A small study has previously suggested 25(OH)D₃ may
398 promote immune tolerance during initial exposure to solids (56), but our study is the first to
399 relate 25(OH)D₃ around the time of weaning to the clinically relevant outcome of challenge-
400 proven food allergy. There was no evidence of an association between VDI at 6 months and
401 food allergy at 1 year of age.

402 Whilst there is consistent evidence of an association between latitudes further from the
403 equator and various proxy markers of food allergy prevalence (10, 11, 14, 57), we were
404 unable to demonstrate an association between UVR exposure measured at the individual level
405 and allergic outcomes. Our measure, which combined ambient UVR and parent-reported time
406 in the sun (35) was associated with 25(OH)D₃ at each time point, and is likely to provide a
407 more accurate estimate than latitude alone, which may be a proxy for a wide range of factors
408 including ethnicity, genetics and microbial environment. Our findings therefore suggest that
409 the relationship between latitude and allergic disease may relate to factors other than
410 25(OH)D₃ status.

411 The strengths of the study include the use of a population-derived cohort with adequate
412 retention rates; measurement of infant 25(OH)D₃ at both birth and during the introduction of
413 solids; delineation of food allergy status by formal food challenge; and detailed measurement
414 of relevant covariates, including UVR exposure at the individual level. We were also able to
415 conduct relevant sensitivity analyses and tests of effect modification, and show that these did
416 not substantially alter the findings. The predominantly Caucasian cohort limits the
417 generalisability of the findings, and this may be important in the context of growing evidence
418 that the relationship between either 25(OH)D (58) or 25(OH)D₃ (45) and food allergy may be
419 modified by genetic factors. On the other hand, the relative homogeneity of the BIS cohort
420 assists internal validity. We did not measure free 25(OH)D and vitamin D binding protein
421 which limited our ability to investigate the role of bioavailable 25(OH)D. The statistical
422 power was limited by the number of food allergy cases and it is important to recognise that
423 the 95% confidence intervals around our point estimates did not exclude potential effects of a
424 relative risk up to about 2-fold. It is also noteworthy that there were only 12 cases of peanut
425 allergy; and the aRR regarding a cross-sectional association between VDI and food allergy at
426 1 year is not inconsistent with the positive association observed among infants of Australian
427 parents in the HealthNuts study (21). We were unable to conduct a meaningful analysis of the
428 relationship between 25(OH)D₃ status and severe eczema as there were very few children
429 with severe eczema in the current study.

430 In conclusion, in a predominantly Caucasian cohort, in which egg was the commonest food
431 allergy, there was no evidence of a longitudinal association between either VDI during the
432 first 6 months of infancy, or UVR exposure, and challenge-proven food allergy at 1 year of
433 age or eczema. Our findings require replication in larger observational studies and/or clinical
434 trials, including a sufficient number of children with peanut allergy, and relating directly
435 measured 25(OH)D₃ to robust measures of clinically relevant food allergy status. Until such
436 studies are completed, the balance of current evidence does not support the widespread
437 implementation of routine vitamin D supplementation during early infancy for the purpose of
438 preventing allergic outcomes.

439

440 **Acknowledgements**

441 We thank the BIS participants for the generous contribution they have made to this project.
442 We also thank current and past staff for their efforts in recruiting and maintaining the cohort
443 and in obtaining and processing the data and biospecimens.

444

445

446 References

447

448

- 449 1. Liew WK, Chiang WC, Goh AE, Lim HH, Chay OM, Chang S, et al. Paediatric anaphylaxis
450 in a Singaporean children cohort: changing food allergy triggers over time. *Asia Pac Allergy*
451 2013;**3**(1):29-34.
- 452 2. Gupta RS, Springston EE, Smith B, Warrier MR, Pongracic J, Holl JL. Geographic variability
453 of childhood food allergy in the United States. *Clin Pediatr (Phila)* 2012;**51**(9):856-861.
- 454 3. Gupta R, Sheikh A, Strachan DP, Anderson HR. Time trends in allergic disorders in the UK.
455 *Thorax* 2007;**62**(1):91-96.
- 456 4. Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ, Matheson MC, et al. Prevalence of
457 challenge-proven IgE-mediated food allergy using population-based sampling and predetermined
458 challenge criteria in infants. *J Allergy Clin Immunol* 2011;**127**(3):668-676.e661-662.
- 459 5. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, Group IPTS. Global
460 variations in prevalence of eczema symptoms in children from ISAAC Phase Three. *J Allergy Clin*
461 *Immunol* 2009;**124**(6):1251-1258 e1223.
- 462 6. Martin PE, Koplin JJ, Eckert JK, Lowe AJ, Ponsonby AL, Osborne NJ, et al. The prevalence
463 and socio-demographic risk factors of clinical eczema in infancy: a population-based observational
464 study. *Clin Exp Allergy* 2013;**43**(6):642-651.
- 465 7. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;**357**(3):266-281.
- 466 8. Vassallo MF, Camargo CA, Jr. Potential mechanisms for the hypothesized link between
467 sunshine, vitamin D, and food allergy in children. *J Allergy Clin Immunol* 2010;**126**(2):217-222.
- 468 9. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency:
469 implications for establishing a new effective dietary intake recommendation for vitamin D. *J Nutr*
470 2005;**135**(2):317-322.

- 471 10. Camargo CA, Jr., Clark S, Kaplan MS, Lieberman P, Wood RA. Regional differences in
472 EpiPen prescriptions in the United States: the potential role of vitamin D. *J Allergy Clin Immunol*
473 2007;**120**(1):131-136.
- 474 11. Mullins RJ, Clark S, Camargo CA. Regional variation in epinephrine autoinjector
475 prescriptions in Australia: more evidence for the vitamin D-anaphylaxis hypothesis. *Ann Allergy*
476 *Asthma Immunol* 2009;**103**(6):488-495.
- 477 12. Osborne NJ, Ukoumunne OC, Wake M, Allen KJ. Prevalence of eczema and food allergy is
478 associated with latitude in Australia. *J Allergy Clin Immunol* 2012;**129**(3):865-867.
- 479 13. Samanek AJ, Croager EJ, Gies P, Milne E, Prince R, McMichael AJ, et al. Estimates of
480 beneficial and harmful sun exposure times during the year for major Australian population centres.
481 *Med J Aust* 2006;**184**(7):338-341.
- 482 14. Vassallo MF, Banerji A, Rudders SA, Clark S, Mullins RJ, Camargo CA, Jr. Season of birth
483 and food allergy in children. *Ann Allergy Asthma Immunol* 2010;**104**(4):307-313.
- 484 15. Vassallo MF, Banerji A, Rudders SA, Clark S, Camargo CA, Jr. Season of birth and food-
485 induced anaphylaxis in Boston. *Allergy* 2010;**65**(11):1492-1493.
- 486 16. Mullins RJ, Clark S, Katelaris C, Smith V, Solley G, Camargo CA, Jr. Season of birth and
487 childhood food allergy in Australia. *Pediatr Allergy Immunol* 2011;**22**(6):583-589.
- 488 17. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, et al. Reversing the
489 defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. *J*
490 *Clin Invest* 2006;**116**(1):146-155.
- 491 18. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, et al. Novel role of the vitamin D
492 receptor in maintaining the integrity of the intestinal mucosal barrier. *Am J Physiol Gastrointest Liver*
493 *Physiol* 2008;**294**(1):G208-216.
- 494 19. Gorman S, Scott NM, Tan DH, Weeden CE, Tuckey RC, Bisley JL, et al. Acute erythematous
495 ultraviolet radiation causes systemic immunosuppression in the absence of increased 25-
496 hydroxyvitamin D3 levels in male mice. *PLoS One* 2012;**7**(9):e46006.
- 497 20. Rudders SA, Camargo CA, Jr. Sunlight, vitamin D and food allergy. *Curr Opin Allergy Clin*
498 *Immunol* 2015;**15**(4):350-357.
- 499 21. Allen KJ, Koplin JJ, Ponsonby AL, Gurrin LC, Wake M, Vuillermin P, et al. Vitamin D
500 insufficiency is associated with challenge-proven food allergy in infants. *J Allergy Clin Immunol*
501 2013;**131**(4):1109-1116, 1116 e1101-1106.
- 502 22. Wegienka G, Havstad S, Zoratti EM, Kim H, Ownby DR, Johnson CC. Association between
503 vitamin D levels and allergy-related outcomes vary by race and other factors. *J Allergy Clin Immunol*
504 2015;**136**(5):1309-1314 e1301-1304.
- 505 23. Gale CR, Robinson SM, Harvey NC, Javaid MK, Jiang B, Martyn CN, et al. Maternal vitamin
506 D status during pregnancy and child outcomes. *Eur J Clin Nutr* 2008;**62**(1):68-77.

- 507 24. Bunyavanich S, Rifas-Shiman SL, Platts-Mills TA, Workman L, Sordillo JE, Camargo CA,
508 Jr., et al. Prenatal, perinatal, and childhood vitamin D exposure and their association with childhood
509 allergic rhinitis and allergic sensitization. *J Allergy Clin Immunol* 2016;**137**(4):1063-1070 e1061-
510 1062.
- 511 25. Chawes BL, Bonnelykke K, Jensen PF, Schoos AM, Heickendorff L, Bisgaard H. Cord blood
512 25(OH)-vitamin D deficiency and childhood asthma, allergy and eczema: the COPSAC2000 birth
513 cohort study. *PLoS One* 2014;**9**(6):e99856.
- 514 26. Mullins RJ, Clark S, Wiley V, Eyles D, Camargo CA, Jr. Neonatal vitamin D status and
515 childhood peanut allergy: a pilot study. *Ann Allergy Asthma Immunol* 2012;**109**(5):324-328.
- 516 27. Jones AP, Palmer D, Zhang G, Prescott SL. Cord blood 25-hydroxyvitamin D3 and allergic
517 disease during infancy. *Pediatrics* 2012;**130**(5):e1128-1135.
- 518 28. Weisse K, Winkler S, Hirche F, Herberth G, Hinz D, Bauer M, et al. Maternal and newborn
519 vitamin D status and its impact on food allergy development in the German LINA cohort study.
520 *Allergy* 2013;**68**(2):220-228.
- 521 29. Kemp AS, Ponsonby AL, Pezic A, Cochrane JA, Dwyer T, Jones G. The influence of sun
522 exposure in childhood and adolescence on atopic disease at adolescence. *Pediatr Allergy Immunol*
523 2013;**24**(5):493-500.
- 524 30. Vuillermin P, Saffery R, Allen KJ, Carlin JB, Tang ML, Ranganathan S, et al. Cohort Profile:
525 The Barwon Infant Study. *Int J Epidemiol* 2015;**44**(4):1148-1160.
- 526 31. Clarke M, Tuckey R, Gorman S, Holt B, Hart P. Optimized 25-hydroxyvitamin D analysis
527 using liquid-liquid extraction with 2D separation with LC/MS/MS detection, provides superior
528 precision compared to conventional assays. *Metabolomics* 2013;**9**(5):1031-1040.
- 529 32. Wagner CL, Greer FR, American Academy of Pediatrics Section on B, American Academy
530 of Pediatrics Committee on N. Prevention of rickets and vitamin D deficiency in infants, children, and
531 adolescents. *Pediatrics* 2008;**122**(5):1142-1152.
- 532 33. In: Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary Reference Intakes for
533 Calcium and Vitamin D. Washington (DC); 2011.
- 534 34. Diffey BL, Jansen CT, Urbach F, Wulf HC. The standard erythema dose: a new
535 photobiological concept. *Photodermatol Photoimmunol Photomed* 1997;**13**(1-2):64-66.
- 536 35. Suaini NH, Koplin JJ, Ellis JA, Peters RL, Ponsonby AL, Dharmage SC, et al. Environmental
537 and genetic determinants of vitamin D insufficiency in 12-month-old infants. *J Steroid Biochem Mol*
538 *Biol* 2014;**144 Pt B**:445-454.
- 539 36. Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick testing in children with
540 food allergy. *Pediatr Allergy Immunol* 2004;**15**(5):435-441.
- 541 37. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic
542 Criteria for Atopic Dermatitis. III. Independent hospital validation. *Br J Dermatol* 1994;**131**(3):406-
543 416.

- 544 38. Fleming S, Bodner C, Devereux G, Russell G, Campbell D, Godden D, et al. An application
545 of the United Kingdom Working Party diagnostic criteria for atopic dermatitis in Scottish infants. *J*
546 *Invest Dermatol* 2001;**117**(6):1526-1530.
- 547 39. Ismail IH, Oppedisano F, Joseph SJ, Boyle RJ, Licciardi PV, Robins-Browne RM, et al.
548 Reduced gut microbial diversity in early life is associated with later development of eczema but not
549 atopy in high-risk infants. *Pediatr Allergy Immunol* 2012;**23**(7):674-681.
- 550 40. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European
551 Task Force on Atopic Dermatitis. *Dermatology* 1993;**186**(1):23-31.
- 552 41. Pucci N, Novembre E, Cammarata MG, Bernardini R, Monaco MG, Calogero C, et al.
553 Scoring atopic dermatitis in infants and young children: distinctive features of the SCORAD index.
554 *Allergy* 2005;**60**(1):113-116.
- 555 42. Lumley T. Complex Surveys: A Guide to Analysis Using R. 1st ed. ed. Hoboken, New
556 Jersey.: John Wiley & Sons.; 2010.
- 557 43. Rubin DB, Little RJ. Statistical analysis with missing data. *Hoboken, NJ: J Wiley & Sons*
558 2002.
- 559 44. De Stavola BL, Nitsch D, dos Santos Silva I, McCormack V, Hardy R, Mann V, et al.
560 Statistical issues in life course epidemiology. *Am J Epidemiol* 2006;**163**(1):84-96.
- 561 45. Koplin JJ, Suaini NH, Vuillermin P, Ellis JA, Panjari M, Ponsonby AL, et al. Polymorphisms
562 affecting vitamin D-binding protein modify the relationship between serum vitamin D (25[OH]D3)
563 and food allergy. *J Allergy Clin Immunol* 2016;**137**(2):500-506 e504.
- 564 46. Kelleher MM, Dunn-Galvin A, Gray C, Murray DM, Kiely M, Kenny L, et al. Skin barrier
565 impairment at birth predicts food allergy at 2 years of age. *J Allergy Clin Immunol* 2016;**137**(4):1111-
566 1116 e1118.
- 567 47. Dogruel D, Bingol G, Altintas DU, Yilmaz M, Guneser Kendirli S. Clinical Features of Food
568 Allergy during the 1st Year of Life: The ADAPAR Birth Cohort Study. *Int Arch Allergy Immunol*
569 2016;**169**(3):171-180.
- 570 48. Assa A, Vong L, Pinnell LJ, Avitzur N, Johnson-Henry KC, Sherman PM. Vitamin D
571 deficiency promotes epithelial barrier dysfunction and intestinal inflammation. *J Infect Dis*
572 2014;**210**(8):1296-1305.
- 573 49. Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, et al. Protective role of 1,25(OH)₂ vitamin D₃
574 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. *BMC*
575 *Gastroenterol* 2012;**12**:57.
- 576 50. Rothers J, Wright AL, Stern DA, Halonen M, Camargo CA, Jr. Cord blood 25-
577 hydroxyvitamin D levels are associated with aeroallergen sensitization in children from Tucson,
578 Arizona. *The Journal of allergy and clinical immunology* 2011;**128**(5):1093-1099 e1091-1095.

- 579 51. Liu X, Arguelles L, Zhou Y, Wang G, Chen Q, Tsai HJ, et al. Longitudinal trajectory of
580 vitamin D status from birth to early childhood in the development of food sensitization. *Pediatr Res*
581 2013;**74**(3):321-326.
- 582 52. Baiz N, Dargent-Molina P, Wark JD, Souberbielle JC, Annesi-Maesano I, Group EM-CCS.
583 Cord serum 25-hydroxyvitamin D and risk of early childhood transient wheezing and atopic
584 dermatitis. *J Allergy Clin Immunol* 2014;**133**(1):147-153.
- 585 53. Visness CM, Sandel MT, O'Connor G, Gern JE, Jaffee KF, Wood RA, et al. Cord blood
586 vitamin D concentrations are unrelated to atopy and wheeze in 2 diverse birth cohort studies. *J Allergy*
587 *Clin Immunol* 2015;**136**(4):1108-1110 e1102.
- 588 54. Roth DE. Vitamin D supplementation during pregnancy: safety considerations in the design
589 and interpretation of clinical trials. *J Perinatol* 2011;**31**(7):449-459.
- 590 55. Molloy J, Ponsonby AL, Allen KJ, Tang ML, Collier FM, Ward AC, et al. Is Low Vitamin D
591 Status A Risk Factor For Food Allergy? Current Evidence And Future Directions. *Mini Rev Med*
592 *Chem* 2015;**15**(11):944-952.
- 593 56. Jones AP, D'Vaz N, Meldrum S, Palmer DJ, Zhang G, Prescott SL. 25-hydroxyvitamin D3
594 status is associated with developing adaptive and innate immune responses in the first 6 months of
595 life. *Clin Exp Allergy* 2015;**45**(1):220-231.
- 596 57. Mullins RJ, Clark S, Camargo CA, Jr. Regional variation in infant hypoallergenic formula
597 prescriptions in Australia. *Pediatr Allergy Immunol* 2010;**21**(2 Pt 2):e413-420.
- 598 58. Liu X, Wang G, Hong X, Wang D, Tsai HJ, Zhang S, et al. Gene-vitamin D interactions on
599 food sensitization: a prospective birth cohort study. *Allergy* 2011;**66**(11):1442-1448.

600

Tables and Figures:

Table I: Participant baseline characteristics

Characteristic	Inception birth cohort (n =1074)	Random subcohort (n=274)	Food allergic (n=61)
Sex of child			
– Male	557 (51.9%)	153 (55.8%)	34 (55.7%)
– Female	517 (48.1%)	121 (44.2%)	27 (44.3%)
Maternal country of birth			
– Australia	946 (88%)	235 (85.8%)	56 (91.8%)
– Other	107 (10%)	32 (11.7%)	5 (8.2%)
– unknown	21 (2%)	7 (2.5%)	0 (0.0%)
Paternal country of birth			
– Australia	923 (85.9%)	233 (85.0%)	49 (80.3%)
– other	109 (10.2%)	25 (9.1%)	8 (13.1%)
– unknown	42 (3.9%)	16 (5.8%)	4 (6.6%)
Participant Caucasian ethnicity			
– yes	772 (71.9%)	206 (75.2%)	43 (70.5%).
– no	299 (27.8%)	67 (24.4%)	17 (27.9%)
– unknown	3 (0.3%)	1 (0.4%)	1 (1.6%)
Number of siblings			
– 0	453 (42.2%)	98 (35.8%)	22 (36.07%)
– 1	383 (35.7%)	112 (40.9%)	28 (45.9%)
– 2	183 (17.0%)	52 (18.9%)	10 (16.3%)
– 3 or more	55 (5.1%)	12 (4.4%)	1 (1.6%)
Pet ownership			
– yes	815 (75.9%)	215 (78.5%)	35 (55.7%)
– no	197 (18.3%)	55 (20.0%)	25 (44.3%)
– unknown	62 (5.8%)	4 (1.5%)	1 (0.0%)
Livestock ownership			
– yes	73 (6.8%)	16 (5.9%)	1 (1.6%)
– no	985 (91.7%)	253 (92.3%)	59 (96.7%)
– unknown	16 (1.5%)	5 (1.8%)	1 (1.6%)

Family history in a first degree relative of			
– asthma	542 (50.5%)	144 (52.5%)	43 (70.5%)
– hay fever	674 (62.8%)	183 (66.8%)	47 (77.1%)
– eczema	480 (44.7%)	135 (49.3%)	40 (65.6%)
– food allergy	265 (24.7%)	65 (23.7%)	16 (26.2%)
Delivery via caesarean section	332 (30.9%)	93 (33.9%)	20 (32.8%)

Gestational age at birth			
– 32 to 36 completed weeks	47 (4.4%)	11 (4.0%)	0 (0.0%)
– 37 to 42 completed weeks	1,027 (95.6%)	263 (96.0%)	61 (100%)
– > 42 completed weeks	0 (0.0%)	0 (0.0%)	0 (0.0%)
Birth weight (kg), mean (SD)	3.53 (0.525)	3.56 (0.556)	3.51 (0.459)
Smoking			
– yes	165 (15.4%)	30 (11.0%)	9 (14.8%)
– no	891 (83.0%)	242 (88.3%)	52 (85.2%)
– unknown	18 (1.6%)	2 (0.7%)	0 (0.0%)
#SEIFA			
– low	268 (25.0%)	66 (24.1%)	15 (24.6%)
– middle	204 (19%)	59 (21.5%)	9 (14.8%)
– high	582 (54.2%)	146 (53.3%)	35 (57.4%)
– unknown	20 (1.9%)	3 (1.1%)	2 (3.2%)
Season of birth			
– autumn	274 (25.5%)	66 (24.1%)	10 (16.4%)
– winter	275 (25.6%)	77 (28.1%)	19 (31.2%)
– spring	309 (28.8%)	52 (19.0%)	17 (27.9%)
– summer	216 (20.1%)	79 (28.8%)	15 (24.6%)
Infant feeding (at six months)			
– breastfed exclusively	429 (39.9%)	113 (41.2%)	29 (47.5%)
– formulafed exclusively	320 (29.8%)	104 (38.0%)	15 (24.6%)
– mixed breast/formula	171 (15.9%)	46 (16.8%)	14 (22.9%)
– unknown	154 (14.4%)	11 (4.0%)	3 (5.0%)
infant feeding (at twelve months)			
– breastfed exclusively	271 (25.2%)	83 (30.3%)	18 (29.5%)
– formulafed exclusively	354 (33.0%)	111 (40.5%)	23 (37.7%)
– mixed breast/formula	260 (24.2%)	89 (28.1%)	18 (29.5%)
– unknown	189 (17.6%)	3 (1.1%)	2 (3.3%)
Introduction of solids in infancy by six months of age			
– yes	896 (83.4%)	256 (93.4%)	55 (90.2%)

- no	24 (2.2%)	7 (2.6%)	3 (4.9%)
- unknown	154 (14.4%)	11 (4.0%)	3 (4.9%)
Maternal antenatal vitamin D supplementation			
- yes	917 (85.4%)	226 (82.5%)	54 (88.5%)
- no	10 (0.9%)	1 (0.4%)	1 (1.6%)
- unknown	147 (13.7%)	47 (17.1%)	6 (9.8%)

#SEIFA, Socio-Economic Indexes for Areas (tertiles)

Table II: Food Allergy prevalence

Food tested	+Sensitised (n) ≥1mm	#Sensitised (n) ≥2mm	Prevalence sensitised ≥2mm		Challenge proven food allergy (n)	Food allergy prevalence	
			%	95% CI		%	95% CI
All Foods	114/805	93/804	11.6	(9.5-13.9)	61/786	7.7	(6.0-9.8)
Raw Egg	83/818	70/818	8.6	(6.8-10.6)	53/808	6.5	(5.0-8.4)
Peanut	41/817	28/817	3.4	(2.3-4.9)	12/812	1.5	(0.8-2.6)
Cashew	21/818	15/818	1.8	(1.1-3.0)	4/816	0.4	(0.1-1.3)
Cow's Milk	11/818	10/818	1.2	(0.6-2.2)	4/815	0.4	(0.1-1.3)
Sesame	3/802	2/802	0.2	(0.0-0.9)	1/801	0.1	(0.0-0.8)

⁺All foods 1 mm sensitised: Infants with a SPT 1 mm or more to one or more of the five foods were compared to infants with negative SPT's to all five foods.

[#]All foods 2 mm sensitised: Infants with a SPT 2 mm or more to one of more of the five foods were compared to infants with negative SPT to all five foods. (A single infant had a 1 mm SPT to a single food but had missing data on other SPT's so had an incomplete SPT and was excluded from the 2 mm sensitisation analysis).

Figure 1: Prevalence of 25(OH)D₃ insufficiency and sufficiency in participants in the random subsample.






Figure 2: Association between vitamin D insufficiency and challenge proven food allergy at 1 year



Adjusted for family history of allergy, ethnicity, number of siblings, domestic pets, formula feeding at six and twelve months. Whiskers represent 95% CI for RR estimates.


Figure 3: Association between vitamin D insufficiency and eczema

^Eczema identified during the first year of life in infants compared to infants without eczema in the random subcohort (n=274).

* Eczema identified between six and twelve months compared with infants who did not develop eczema within the random subcohort (n=274). Infants with eczema identified at six months of age or earlier were excluded (n=19).

Adjusted for family history of allergy, ethnicity, number of siblings, domestic pets and formula feeding at six months. Whiskers represent 95% CI for RR estimates.

Figure 4: Adjusted association between UVR exposure dose and challenge proven food allergy at 1 year in the whole cohort



Y axis: UVR exposure divided into quintiles at Trimester 1, Trimester 2, 6 and 12 months and lowest quintile used as baseline comparison group.

^At 4 weeks 40% of infants were reported to have minimal or no exposure to direct sunlight so UVR exposure dose at 4 weeks is divided into quartiles and lowest quartile used as baseline comparison group.

Adjusted for family history of allergy, ethnicity, number of siblings and domestic pets. Whiskers represent 95% CI for RR estimates.